UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 2, pp. 141 - 148
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Reproducibility of Results | Prognosis | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Male | Survival Rate | Kidney Neoplasms - mortality | Kidney Neoplasms - diagnosis | Carcinoma, Renal Cell - mortality | Neoplasm Metastasis | Models, Biological | Carcinoma, Renal Cell - diagnosis | Female | Kidney Neoplasms - pathology | Aged | Databases, Factual | Consortia | Databases | Carcinoma | Models | Metastasis | Nanotechnology | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 297 - 305
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Lymph Nodes - pathology | Follow-Up Studies | Lymph Nodes - surgery | Humans | Middle Aged | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - physiopathology | Disease-Free Survival | Neoplasm Grading | Neoplasm Micrometastasis | Breast Neoplasms - pathology | Axilla | Adult | Female | Aged | Sentinel Lymph Node Biopsy | Surgery | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovary - drug effects | Chemotherapy, Adjuvant | Drug Administration Schedule | Risk Assessment | Administration, Oral | Early Detection of Cancer | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Premenopause - physiology | Survival Analysis | Quality of Life | Breast Neoplasms - mortality | Tamoxifen - adverse effects | Neoplasm Staging | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2963 - 2969
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Medical Oncology - methods | ras Proteins - genetics | Amenorrhea - physiopathology | Proto-Oncogene Proteins p21(ras) | Randomized Controlled Trials as Topic - methods | Bias | Colorectal Neoplasms - genetics | Humans | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Breast Neoplasms - physiopathology | Breast Neoplasms - therapy | Disease-Free Survival | Survival Analysis | Female | Clinical Trials as Topic - methods | Mutation | Research Design | Index Medicus | Stat | Bios3 | Statistics in Oncology
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1101 - 1108
Hematology, Oncology and Palliative Medicine | South America | Triazoles - administration & dosage | Breast Neoplasms - secondary | Humans | North America | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Receptors, Steroid - analysis | Breast Neoplasms - chemistry | Neoplasms, Second Primary | Time Factors | Postmenopause | Female | Aromatase Inhibitors - administration & dosage | Double-Blind Method | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Selective Estrogen Receptor Modulators - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Cross-Over Studies | New Zealand | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | South Africa | Australia | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | General aspects | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Estrogens | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Breast (Edinburgh), ISSN 0960-9776, 11/2019, Volume 48 Suppl 1, pp. S23 - S25
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 17, pp. 1516 - 1517
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 34, pp. 5569 - 5575
Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Predictive Value of Tests | Prognosis | Humans | Proportional Hazards Models | Antineoplastic Agents - therapeutic use | Breast Neoplasms | Endocrine System | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Postmenopause | Female | Ki-67 Antigen - biosynthesis | Chemotherapy, Adjuvant | Cohort Studies | Nitriles - therapeutic use | Triazoles - therapeutic use | Index Medicus | Breast Cancer | Antineoplastic Agents | Hormonal | Tamoxifen | Chemotherapy | Triazoles | Ki-67 Antigen | biosynthesis | Nitriles | Adjuvant | Cancer and Oncology | therapeutic use | Cancer och onkologi
Journal Article
Clinical cancer research, ISSN 1078-0432, 07/2009, Volume 15, Issue 14, pp. 4706 - 4711
Prostate cancer | Needle biopsies | TMPRSS2-ERG | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the urinary system | Urinary tract. Prostate gland | Gynecology. Andrology. Obstetrics | Pharmacology. Drug treatments | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Antineoplastic agents | Male genital diseases | Tumors | Transcriptional Regulator ERG | Multivariate Analysis | Prostatic Neoplasms - pathology | Prospective Studies | United States | Gene Frequency | Humans | Middle Aged | In Situ Hybridization, Fluorescence | Logistic Models | Male | Prostate-Specific Antigen - analysis | Prostate - metabolism | Prostate - pathology | Prostatic Neoplasms - genetics | Biopsy | Oncogene Proteins, Fusion - genetics | Serine Endopeptidases - genetics | Trans-Activators - genetics | Aged | Index Medicus
Journal Article
12.
Full Text
Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2004, Volume 43, Issue 4, pp. 678 - 683
Heart rate | General Clinical Research Center | C-reactive protein | Partial sleep deprivation | Interleukin | Blood pressure | Analysis of variance | Total sleep deprivation | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Humans | Male | Risk | Biomarkers - blood | Inflammation - blood | Monitoring, Physiologic | Time Factors | Cardiovascular Diseases - epidemiology | Heart Rate - physiology | Adult | Female | Blood Pressure - physiology | C-Reactive Protein - analysis | Sleep Deprivation - blood | Heart | Cytokines | Review boards | Experiments | Sleep deprivation | Studies | Proteins | Body mass index | Hypotheses | Sleep | Hospitals | Age
Journal Article